← All trials
NCT05186285
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jan 11, 2022
- Last posted
- Feb 11, 2022
- Enrollment
- 66
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Keymed Biosciences Co.LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.